Marketing Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod

When an FDA advisory panel narrowly backed Eli Lilly’s Cyramza for use in newly diagnosed non-small cell lung cancer (NSCLC), a final approval didn’t seem so certain. Now, the company can breathe a sigh of relief, as the agency has decided to follow the experts’ recommendation.

Friday, the FDA greenlighted Cyramza in combination with Roche’s Tarceva for previously untreated NSCLC with EGFR mutations.